• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news

Flinn Foundation commits $5.52M to College of Medicine – Phoenix
The gift will establish two research faculty positions and support training to further translational research in cardiovascular diseases, neurosciences and mental health. April 7, 2022 University Alumni and Development Programflinn-gift-web.jpg Lauren MacDonnell, a research associate in the Translational Cardiovascular Research Center, processes samples in the TCRC lab. Sun Belous/College of Medicine – Phoenix Marketing and CommunicationsHealthCollege of Medicine - PhoenixCollege of PharmacyCompassion Media contact(s)Beth Smith College of Medicine – Phoenixbhsmith1@arizona.edu602-827-2676TheFlinn Foundation has...
Source: The University of Arizona: Health - April 6, 2022 Category: Universities & Medical Training Authors: mittank Source Type: research

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news